• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sofosbuvir, ribavirin achieve high rates of Hepatitis C virus remission in toughest cases

bys25qthea
August 28, 2013
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Participants treated for 24 weeks with sofosbuvir and either weight-based or low-dose ribavirin achieved undetectable viral loads of 68% and 48% respectively. 

2. Factors associated with relapse include male sex, advanced liver disease, and high baseline Hepatitis C virus RNA before treatment. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Hepatitis C virus (HCV) is a major cause of end-stage liver disease and hepatocellular carcinoma in the United States.  Data is limited on the efficacy of direct-acting antiviral agents in achieving HCV remission in populations with unfavorable treatment characteristics. This study determined the efficacy of sofosbuvir combined with either weight-based or low-dose ribavirin by determining viral loads or sustained virologic response (SVR24) at 24 weeks of treatment. The participants were predominantly African American, male, obese, with unfavorable HCV genotypes, and high baseline HCV RNA levels.  By 24 weeks, 68% of participants had SVR24 in the weight-based ribavirin group, and 48% of participants had SVR24 in the low-dose ribavirin group. The study found that male sex, advanced liver disease, and high baseline HCV RNA contributed to higher rates of relapse. Strengths of study include using a population that generally has poor treatment outcomes to traditional HCV therapies, which may be representative of the populations where HCV is epidemic in the U.S. Limitations include the small sample size. The study may inform future practice by providing evidence of the effectiveness of an interferon-free regimen for HCV treatment in difficult to treat patients.

Click to read the study published today in JAMA

RELATED REPORTS

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

Relevant Reading: Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

In-Depth [single-center, randomized, phase 2 trial]: This study determined the efficacy of sofosbuvir with weight-based or low dose ribavirin on HCV genotype 1 remission for 60 patients in a representative population associated with poor treatment outcomes. In part 1 (proof of concept), 10 participants with early to moderate liver fibrosis were treated with sofosbuvir and weight-based ribavirin. Ninety percent (95% CI, 55-100%) achieved undetectable viral loads at 24 weeks of treatment (SVR24). In part 2, 50 participants with all stages of fibrosis were randomized into 2 groups with sofosbuvir combined with either weight-based or low-dose ribavirin. Ninety six percent of participants in both groups achieved viral suppression by week 4. When treated with sofosbuvir and weight-based ribavirin, 68% (95% CI, 46-85%) of participants achieved SVR24, compared to 48% (95% CI, 28-69%, P = 0.20) who achieved SVR24 with sofosbuvir and low-dose ribavirin. Male sex, advanced liver disease, and higher baseline HCV viral loads were associated with relapse. A statistically significant slower rate of viral clearance was found in relapsing patients versus those patients who achieved SVR24 (clearance, 3.57/d vs 5.60/d respectively; P = .009).

By Gayatri Boddupalli and Brittany Hasty

More from this author: Racial differences in breast cancer survival remain large, unchanged, Early surgical intervention for mitral regurgitation associated with greater long-term survival

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: hepatitis C
Previous Post

New genetic link between type 2 diabetes and coronary heart disease

Next Post

Three ultrasonographic findings portend increased risk of malignancy in thyroid nodules

RelatedReports

Study lends support for interferon-free treatment of hepatitis C
2 Minute Medicine

Machine learning model demonstrates superior screening efficiency for Hepatitis C virus carriers

November 29, 2024
#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
StudyGraphics

#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

September 7, 2023
Screening insufficient for newborns exposed to hepatitis C virus
Gastroenterology

Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018

August 31, 2023
Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

July 26, 2022
Next Post
Three ultrasonographic findings portend increased risk of malignancy in thyroid nodules

Three ultrasonographic findings portend increased risk of malignancy in thyroid nodules

The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]

Angiotensin-receptor blockers in diabetic nephropathy [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.